Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature

References 

1. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double-blind placebo-controlled multicenter study. Anticancer Res. 1999;19:3383–3392
   • MEDLINE
2. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised, placebo-controlled trials. Cancer. 2000;88:1082–1090
   • MEDLINE
3. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735–1744
   • MEDLINE
4. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–2
5. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117
   • Full Text
   • Full-Text PDF (117 KB)
6. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253–4254
   • MEDLINE
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
   • Abstract
   • Full Text
   • Full-Text PDF (234 KB)
8. Estillo CL, Van Poznak CH, Williams CH, Evtimovska E, Tkach L, Halpern JL, et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosohonates: a retrospective study [abstract]. J Clin Oncol. 2004;23:750S;(Suppl)
9. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104–1107
   • Full Text
   • Full-Text PDF (177 KB)
10. Durie BGM, Katz M, McCoy J, Crowley J. Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia and Zometa use [abstract]. Blood. 2004;104:216A;(Suppl)
11. Thakkar SG, Isada C, Smith J, Karam MA, Reed J, Tomford JW, et al. Bisphosphonate therapy associated with an increased incidence of mandibular/maxillary osteomyelitis in multiple myeloma patients [abstract]. Blood. 2004;104:313B;(Suppl)
12. Schuster MW, Dymek JM. Oral cavity avascular bone necrosis: a newly recognized complication of intravenous (IV) bisphosphonate therapy in cancer patients [abstract]. Blood. 2004;104:308B;(Suppl)
13. Kut V, Mehta J, Tariman J, Olsson A, Singhal MD. Osteonecrosis of the jaw in myeloma patients receiving pamidronate and zoledronate [abstract]. Blood. 2004;104:315B;(Suppl)
14. Van Poznak CH, Estillo CL, Sauter MP, Hudis CA, Williams T, Tunick T, et al. Osteonecrosis of the jaw in patients with metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2004;88:131S;(Suppl)
15. Carter G, Goss AN, Doecke C. Bisphosphonates and vascular necrosis in the jaw: a possible association. Med J Aust. 2005;182:413–415
    • MEDLINE
16. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34:120–123
    • MEDLINE
17. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71:111–113
18. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182:417–418
    • MEDLINE
19. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006;81:73–75
    • MEDLINE
20. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945–952
21. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emergine oral complication of supportive cancer therapy. Cancer. 2005;104:83–93
    • MEDLINE
22. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates — histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155–160
    • MEDLINE
23. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac. 2006;2:7–14
24. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws: June 2004. professional education material: Novartis, June 2004.
25. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the colesterol biosynthesis pathway in keratinocyte model for esophageal irritation. Mol Pharmacol. 2001;59:193–2002
    • MEDLINE
26. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the Hip: a prospective open-label study. Rheumatology. 2005;44:352–359
27. Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol. 2006;132:114
    • MEDLINE
28. Peters E, Lovas GL, Wysocki GP. Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol. 1993;75:739–743
    • MEDLINE
29. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580–8587
    • MEDLINE
30. Jones JR, Lehtinen T, Riphagen FE, von Roemeling R. Adverse event (AE) reporting of oral clodronate with emphasis on osteonecrosis of the iaws [abstract]. In: Presented at the annual meeting of the American Society for clinical oncology. 2005;p. 799;Abstract
31. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006;35(4):236–243
    • MEDLINE